Cargando…
PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV
Severe Acute Respiratory Syndrome (SARS) is a deadly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV. However, safe and potent adjuvants, especially with more efficient and economical needle-free vaccination are always ne...
Autores principales: | Gai, Wei-wei, Zhang, Yan, Zhou, Di-han, Chen, Yao-qing, Yang, Jing-yi, Yan, Hui-min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SP Wuhan Institute of Virology, CAS
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091335/ https://www.ncbi.nlm.nih.gov/pubmed/21468931 http://dx.doi.org/10.1007/s12250-011-3183-z |
Ejemplares similares
-
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
por: Liu, Yuan, et al.
Publicado: (2021) -
IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant
por: Wang, Jingxia, et al.
Publicado: (2023) -
Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice
por: Maltseva, Mariam, et al.
Publicado: (2022) -
Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein
por: Sengupta, Anirban, et al.
Publicado: (2022) -
Return of the pika: American pikas re‐occupy long‐extirpated, warm locations
por: Millar, Constance I., et al.
Publicado: (2022)